Serum proprotein convertase subtilisin/Kexin type 9 and vascular disease in type 2 diabetic patients
暂无分享,去创建一个
G. Sesti | G. Mannino | F. Andreozzi | F. Montecucco | F. Carbone | M. Bertolotto | L. Liberale | E. Succurro | M. Perticone | A. Sciacqua | T. V. Fiorentino | V. Cassano | G. Armentaro | S. Minetti
[1] M. Scuruchi,et al. PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy , 2022, Biomolecules.
[2] Cheng-gang Zhu,et al. The predictive utility of circulating PCSK9 levels on diabetes mellitus , 2021, Cardiovascular Diabetology.
[3] G. Ning,et al. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study , 2020, Cardiovascular Diabetology.
[4] Yuan-Lin Guo,et al. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study , 2020, Cardiovascular Diabetology.
[5] G. Sesti,et al. Uric Acid and Vascular Damage in Essential Hypertension: Role of Insulin Resistance , 2020, Nutrients.
[6] P. Stone,et al. Arterial stiffness and microvascular disease in type 2 diabetes , 2020, European journal of clinical investigation.
[7] G. Limongelli,et al. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition , 2020, BioFactors.
[8] G. Hovingh,et al. PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia. , 2019, European journal of preventive cardiology.
[9] Yuan-Lin Guo,et al. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy , 2019, Journal of Translational Medicine.
[10] Wen Guo,et al. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[11] W. Spiering,et al. Arterial stiffness as a risk factor for cardiovascular events and all‐cause mortality in people with Type 2 diabetes , 2019, Diabetic medicine : a journal of the British Diabetic Association.
[12] F. Fallarino,et al. PCSK9 at the crossroad of cholesterol metabolism and immune function during infections , 2017, Journal of cellular physiology.
[13] Y. Zhang,et al. Plasma PCSK9 levels are unrelated to arterial stiffness in a community-based, 4.8-year prospective study , 2017, Journal of Human Hypertension.
[14] M. Banach,et al. PCSK9 and diabetes: is there a link? , 2017, Drug discovery today.
[15] P. Magni,et al. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study , 2017, Journal of the American Heart Association.
[16] A. Hamsten,et al. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors , 2016, Circulation.
[17] Jennifer G. Robinson,et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.
[18] Jennifer G. Robinson,et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.
[19] Cheng-gang Zhu,et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. , 2014, Journal of clinical lipidology.
[20] Yuan-Lin Guo,et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. , 2014, Atherosclerosis.
[21] Y. Jang,et al. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. , 2013, Metabolism: clinical and experimental.
[22] F. Arturi,et al. Association between One-Hour Post-Load Plasma Glucose Levels and Vascular Stiffness in Essential Hypertension , 2012, PloS one.
[23] J. Filipovský,et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. , 2012, Journal of hypertension.
[24] E. Ortega,et al. White blood cell count is associated with carotid and femoral atherosclerosis. , 2012, Atherosclerosis.
[25] Jonathan C. Cohen,et al. Genetic and metabolic determinants of plasma PCSK9 levels. , 2009, The Journal of clinical endocrinology and metabolism.
[26] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[27] G. Sesti,et al. Metabolic and cardiovascular risk factors in subjects with impaired fasting glucose: the 100 versus 110 mg/dL threshold , 2007, Diabetes/metabolism research and reviews.
[28] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.
[29] Albert Hofman,et al. Arterial Stiffness and Risk of Coronary Heart Disease and Stroke: The Rotterdam Study , 2006, Circulation.
[30] S. Laurent,et al. Aortic Stiffness Is an Independent Predictor of Fatal Stroke in Essential Hypertension , 2003, Stroke.
[31] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .